Currently, Day One Biopharmaceuticals Inc [DAWN] is trading at $14.72, up 1.73%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DAWN shares have gain 1.73% over the last week, with a monthly amount glided 8.08%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on October 09, 2024, when Needham reiterated its Buy rating and also boosted its price target to $33 from $32. Previously, BofA Securities upgraded its rating to Buy on August 01, 2024, and elevated its price target to $24. On April 24, 2024, Needham reiterated its Buy rating and revised its price target to $33 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $9 on April 25, 2023. CapitalOne initiated its recommendation with a Overweight and recommended $40 as its price target on February 08, 2023. In a note dated December 15, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $35 on this stock.
This stock has fluctuated between a low of $10.90 and a high of $18.07 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $38.8 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $14.72 at the most recent close of the market. An investor can expect a potential return of 163.59% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -7.34%, Pretax Profit Margin comes in at -2.9%, and Net Profit Margin reading is -2.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.22 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.91 points at the first support level, and at 13.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.88, and for the 2nd resistance point, it is at 17.04.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Day One Biopharmaceuticals Inc [NASDAQ:DAWN] is 4.09. Also, the Quick Ratio is 4.09, while the Cash Ratio stands at 10.64. Considering the valuation of this stock, the price to sales ratio is 157.73, the price to book ratio is 4.21.
Transactions by insiders
Recent insider trading involved SAMUEL BLACKMAN, Officer, that happened on Oct 31 ’24 when 30000.0 shares were purchased. HEAD OF R&D, Blackman Samuel C. completed a deal on Sep 10 ’24 to sell 30000.0 shares. Meanwhile, GENERAL COUNSEL Dubow Adam sold 3202.0 shares on Aug 16 ’24.
